Low prevalence of germline BRCA1 mutations in early onset breast cancer without a family history EDITOR-Germline mutations in the BRCA1 and BRCA2 genes cause predisposition to breast and ovarian cancer.
1
Epidemiological evidence and linkage studies suggested that the likelihood that a woman with breast cancer has a genetic susceptibility to the condition is greater the younger she was at diagnosis and with increasing extent of family history of the disease. Studies of the prevalence of germline mutations in BRCA1 and BRCA2 in women with breast cancer has enabled the frequency of mutations to be determined in women with diVerent ages at diagnosis and extent of family history of breast cancer. 2 3 The CASH study into the attributable risk of breast and ovarian cancer estimated that 33% of all breast cancers diagnosed by the age of 29 years, and 22% diagnosed by the age of 30-39 years, are the result of an inherited mutation. 4 However, the proportion of breast cancer cases diagnosed by 40 years resulting from a BRCA1 mutation was predicted to be 5.3%. 5 Previous population based studies of the prevalence of BRCA1 mutations in early onset breast cancer have been in cases unselected for family history, and the majority of mutation carriers detected did have some degree of family history of either breast or ovarian cancer. [6] [7] [8] [9] [10] The aim of this study was to establish the prevalence of BRCA1 mutations in a large series of British patients with a young age of onset and no known family history of the disease, since such patients are referred relatively frequently for genetic counselling. The presence of BRCA1 mutations in a significant proportion of these patients would have important implications for the planning of a mutation screening strategy in diagnostic services.
Patients were ascertained from the Imperial Cancer Research Fund Clinical Breast Oncology Department at Guy's Hospital, and the family cancer clinics at the Genetics Departments of Guy's Hospital and the Royal Free Hospital, both in London, and from St Mary's Hospital, Manchester. The Manchester cases were initially ascertained as part of a population based series for other studies. Patients without a known family history of breast or ovarian cancer at referral were recruited into this study, and these patients were interviewed at home by a genetic nurse counsellor. A family history was taken by the clinical geneticist or genetic nurse counsellor, and the diagnosis confirmed in all probands with either the referring breast unit or the patient's GP or oncologist. Patients with a known family history of breast or ovarian cancer at referral were excluded from the study. The range of age of diagnosis was 22-35 years and the median age of diagnosis was 31 years. Blood samples were taken after the purpose of the study had been explained and informed consent obtained. Full genetic counselling was provided, following agreed protocols, and results were made available to those women wishing to be informed.
The 22 BRCA1 coding exons were amplified using 24 pairs of primers (exon 11 was amplified in three overlapping fragments). The fluorescent chemical cleavage of mismatch (FCCM) protocol was adapted from the method of Rowley et al. 11 PCR products were labelled by incorporation of dUTP analogues which were labelled with either R110 (blue), R6G (green), or Tamra (yellow) fluorescent dyes (PE Applied Biosystems Inc), and heteroduplex molecules then subjected to hydroxylamine modification and piperidine cleavage. Using the three different dyes to label the 24 PCR products that cover the complete BRCA1 coding sequence, three patients could be analysed for one fragment in one lane of the gel; thus three patients were completely screened in 24 lanes and six patients were screened on a 50 well gel. The FCCM technique has been reported to detect over 95% of mutations in a blind study of haemophilia A patients. 11 We evaluated the sensitivity of our BRCA1 protocol by examination of the eight polymorphisms that have been reported in the BRCA1 gene with a frequency of at least 5% (1186A/G, 2201C/T, 2430T/C, 2731C/T, 3232A/G, 3667A/G, 4427C/T, 4956A/G). 12 These polymorphisms were all detected reproducibly at the expected frequency in a panel of over 400 patients who were tested, as part of our continuing studies. In addition, FCCM detected the mutations in three known BRCA1 positive samples (188del 11bp, 5242 C/A, and 5382insC) that were previously found in our laboratory by SSCP analysis. 13 The fluorescent chemical cleavage assay which we have developed therefore allows a rapid and sensitive mutation screen of BRCA1.
Four mutations that were likely to be pathogenic were detected in 110 patients (3.6%) and are listed in table 1. These included three sequence variants that would be predicted to result in premature termination of translation. The 185delAG frameshift mutation, which is prevalent in the Ashkenazi Jewish population, was identified in a British patient (91032) with Jewish ancestry. The 4693-4694delAA mutation was detected in a British patient (78750) who was diagnosed with breast cancer at the age of 26 years. The truncating mutation 3875-3878delGTCT was seen in a patient of Afro-Caribbean origin (94641), who was diagnosed with breast cancer aged 33 years and with a second primary cancer at 38 years. Testing for this mutation in the parents of the patient indicated that it was inherited from her father. A novel in frame deletion, 1965-1967delTCT, was detected in a patient of West African origin (103727) who was diagnosed with breast cancer at the age of 27 years. This mutation would be predicted to result in the deletion of a single amino acid, serine 616, but would not lead to premature termination of translation. This sequence change was absent in over 350 control chromosomes in our study and fulfils all the other criteria for pathogenic status. 13 The pedigrees of these four women are shown in fig 1. Although all four patients originally reported no family history of breast cancer, further investigation showed that the maternal great grandmother of patient 103727 was diagnosed with the disease at about 60 years of age. The lack of a history of breast or ovarian cancer in these families is likely to result from a combination of factors including paternal transmission of the mutation, chance, and reduced penetrance.
Eight other rare DNA sequence variants were identified (table 2). Three of these would not be predicted to alter the expression of BRCA1 or the sequence of its encoded protein (Q1604Q, IVS22+8T/C, UGA+36T/C) and R1347G was present in a patient with a frameshift mutation. 12 The pathogenic status of the other four (Q804H, S1140G, P1637L, and M1652I) remains inconclusive in the absence of a functional assay for the BRCA1 protein. At present, screening panels of ethnically matched controls is a useful means of excluding missense mutations as pathogenic mutations of high penetrance, and it would be helpful if this information was provided in the Breast Cancer database (www.nhgri.nih.gov/Intramural_research/ Lab_transfer/Bic/index.html).
Our detection of pathogenic BRCA1 mutations in 3.6% of young breast cancer patients without a family history of breast or ovarian cancer is consistent with the estimate of Ford et al 5 that the proportion of breast cancer cases in the general population resulting from BRCA1 is 5.3% below the age of 40 years. A recent population based study of young British breast cancer patients unselected for family history found BRCA1 mutations in nine of 254 (3.5%) women diagnosed by the age of 36 years. 8 In North American studies of BRCA1 mutations in women unselected for family history and diagnosed below the age of 35 years, Langston et al 7 Jewish patients who have founder mutations and some patients with a family history. Since we did not screen the promoter region of BRCA1 or for deletions of entire exons, 14 we cannot exclude the possibility that some mutations were missed, and the pathogenic status of several sequence variants remains unresolved. However, the important practical implication of our study is that, given the time and expense involved, it would be reasonable to attach a low priority to BRCA1 mutation screening of young isolated cases of breast cancer in the context of the provision of a publicly funded and cost eVective diagnostic service. A screen of this cohort of patients for BRCA2 mutations is in progress. Delineation of a new syndrome: clustering of pyloric stenosis, endometriosis, and breast cancer in two families EDITOR-Familial tendencies have previously been observed for congenital pyloric stenosis, endometriosis, and breast cancer. These conditions have never been considered to have shared aetiological origins and consequently no previous attempts have been made to investigate an association. For example, when obtaining family history information for a child with pyloric stenosis, one would not routinely request a description of adult onset conditions such as endometriosis or breast cancer. Two families sharing an unusual clustering of these three conditions (pyloric stenosis, endometriosis, and breast cancer) were ascertained at the familial cancer clinics of the Women's College and Princess Margaret Hospitals in Toronto. Family 1 (fig 1) contains four confirmed cases of breast cancer (below age 60), seven cases of endometriosis, five cases of congenital pyloric stenosis, nine cases of polycystic ovaries, and four cases of non-insulin dependent diabetes. In a second unrelated family, a woman previously diagnosed with premenopausal breast cancer, endometriosis, and pyloric stenosis reported one other case of congenital pyloric stenosis and four other cases of endometriosis in her family (fig 1) . It is the similar and unusual presentation in these two families which suggests that the clustering of pyloric stenosis, endometriosis, and breast cancer may not be the result of chance.
A family history of breast cancer is known to be the most significant risk factor for developing the disease. Approximately 5-10% of all cases are hereditary and accounted for by mutations in cancer susceptibility genes BRCA1 and BRCA2. 1 2 Family 1 met our criteria for BRCA1 and BRCA2 testing, with four known cases of breast cancer diagnosed below the age of 60. Mutation analysis by direct sequencing of the coding regions of BRCA1 and BRCA2 as well as 1700 adjacent non-coding intronic base pairs was performed by Myriad Genetic Laboratories (http:// www.myriad.com). No BRCA mutation was identified for family 1. Family 2 was not tested for BRCA1 or BRCA2 mutations.
The aetiology of endometriosis remains uncertain, although familial trends have been described. 3 Four studies found that there is an increased risk among first degree relatives. [4] [5] [6] [7] A small twin study found 6/8 monozygotic and 0/2 dizygotic twin pairs had endometriosis. 7 In family 2, five women in three generations had endometriosis and in family 1 seven women in three generations were given the diagnosis. The pattern of inheritance is consistent with sex limited, autosomal dominant inheritance.
A multifactorial genetic contribution for pyloric stenosis has been well established, although its pathological basis remains unknown. Twin studies have shown that there is a 25-40% concordance rate in monozygotic twins. 8 9 Based on pooled data from several family studies and assuming a population prevalence of 0.3%, a relative risk for first degree relatives compared to the general population was 18 10 ; however, population based studies (unselected patients) have not been done. Pyloric stenosis has recently been linked to the locus of the neuronal nitric oxide synthase (NOS1) gene, based on 27 families. 11 The NOS1 locus was also examined for other multifactorial conditions such as asthma (candidate gene) 13 14 and multiple sclerosis (no association).
15 Family 1 has five documented cases of surgically corrected pyloric stenosis in three males and two females. Family 2 has a parent and child with PS, both female.
In addition to endometriosis, family 1 contains nine women with polycystic ovary syndrome (PCOS), including one woman with non-insulin dependent diabetes mellitus (NIDDM). PCOS and NIDDM have been shown to have a shared aetiology. 12 Women with PCOS have a unique disorder of insulin action and are at increased risk of developing NIDDM, which occurs substantially younger (in the third to fourth decades) than it does in the general population.
Breast cancer, endometriosis, and pyloric stenosis in families 1 and 2 may be explained by separate genetic predispositions; however, the possibility that there is a common genetic basis exists. It is the complex interplay between environmental, hormonal, and genetic factors which poses a challenge to understanding the aetiology of
